OGEN Oragenics Inc.

0.6
-0.01  -2%
Previous Close 0.61
Open 0.61
Price To Book 1.94
Market Cap 27,674,882
Shares 46,124,803
Volume 1,063,943
Short Ratio 2.57
Av. Daily Volume 946,986
Stock charts supplied by TradingView

NewsSee all news

  1. Oragenics, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference

    Oragenics, Inc. (NYSE:OGEN), a leader in the development of effective treatments for oral mucositis and new antibiotics against infectious diseases, announced today that Alan Joslyn, Ph.D., president and CEO of

  2. Oragenics Inc. to Present at the LD Micro 12th Annual Main Event on December 10, 2019

    Oragenics, Inc. (NYSE:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced that Alan Joslyn, Ph.D., president and CEO of

  3. Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis

    Oragenics, Inc. (NYSE:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced the completion of enrollment in its ongoing

  4. Oragenics, Inc. Publishes Peer-Reviewed Study in Journal of Peptide Science Demonstrating First Complete Chemical Synthesis of Bicyclic Ring of a Mutacin 1140 Analog

    Oragenics, Inc. (NYSE:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis ("OM"), today announces the publication of the outcome of the a

  5. Intrexon Reports Third Quarter 2019 Financial Results

    GERMANTOWN, Md., Nov. 12, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ:XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 completion of enrolment announced December 2, 2019 with data due early 2020.
AG013
Oral mucositis (OM)

Latest News

  1. Oragenics, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference

    Oragenics, Inc. (NYSE:OGEN), a leader in the development of effective treatments for oral mucositis and new antibiotics against infectious diseases, announced today that Alan Joslyn, Ph.D., president and CEO of

  2. Oragenics Inc. to Present at the LD Micro 12th Annual Main Event on December 10, 2019

    Oragenics, Inc. (NYSE:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced that Alan Joslyn, Ph.D., president and CEO of

  3. Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis

    Oragenics, Inc. (NYSE:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced the completion of enrollment in its ongoing

  4. Oragenics, Inc. Publishes Peer-Reviewed Study in Journal of Peptide Science Demonstrating First Complete Chemical Synthesis of Bicyclic Ring of a Mutacin 1140 Analog

    Oragenics, Inc. (NYSE:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis ("OM"), today announces the publication of the outcome of the a

  5. Intrexon Reports Third Quarter 2019 Financial Results

    GERMANTOWN, Md., Nov. 12, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ:XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its

  6. Oragenics, Inc. SVP of Discovery Research, Martin Handfield, Ph.D. to Be Featured Speaker at the International Conference on Microbial Research and Applications

    Oragenics, Inc. (NYSE:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announces the company's Senior Vice President of Discovery

  7. Oragenics Presents Interim Data on The AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019

    Oragenics, Inc. (NYSE:OGEN) ("Oragenics"), a leader in the development of novel antibiotics against infectious diseases and effective treatments for oral mucositis, today announces initial data from its ongoing Phase 2,

  8. Oragenics, Inc. Announces Phase 2 Clinical Trial of AG013 Reaches Enrollment of 158 Patients

    Oragenics, Inc. (NYSE:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announces it has enrolled 158 patients in its Phase 2 trial of

  9. Oragenics, Inc. to Present Interim Data on AG013 at the European Society of Medical Oncology Congress

    Oragenics, Inc. (NYSE:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis ("OM"), today announces that an abstract from its ongoing double-blind,

  10. Oragenics Inc. to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference

    Oragenics, Inc. (NYSE:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis ("OM"), today announced that Alan Joslyn, president and CEO of